Immunotherapy and Antiangiogenic Therapy for the Treatment of Patients With Advanced Renal Cell Carcinoma: A Systematic Review and an Updated Network Meta-Analysis of Phase III Clinical Trials.

Cureus · 2023 · PMC10254091 · PMID 37303368

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

a favorable trendP < 0.00001actually significant

Combined immunotherapy and antiangiogenic therapy also showed a favorable trend compared to Sunitinib regarding objective response rate (OR=2.53 (2.23, 2.87), P < 0.00001) (Figure 4 ).

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.